Acknowledgement to Referees
- PDF / 467,238 Bytes
- 4 Pages / 595.276 x 790.866 pts Page_size
- 44 Downloads / 217 Views
ACKNOWLEDGEMENT TO REFEREES
Acknowledgement to Referees
© Springer Nature Switzerland AG 2019
Dear Reader, As we reach the final issue of Targeted Oncology for 2019, we wish to reflect on another successful year’s achievements, and to thank all those who have contributed their time and effort to guarantee the high quality of our content. Over 70 articles have been published; the most popular of these, in terms of downloads from SpringerLink, have been: • Maximilian J. Hochmair et al. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to
Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
• Michael Moran et al. Sunitinib for MetastaticRenalCell Carcinoma: A SystematicReview and Meta-Analysis of Real-
Worldand Clinical Trials Data
• Sarah Sammons et al. Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Posit
ive Advanced Breast Cancer
• Chang Liu et al. Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer in Routine
Clinical Practice
• Neal Shore et al. Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darol • • • • •
utamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the PhaseIII ARAMIS Trial Anna Buder et al. EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR Maja J. A. de Jonge et al. PhaseI Studyof BI 853520, an Inhibitor of FocalAdhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies Xiaonan Hong et al. Pralatrexate in Chinese Patients with Relapsed or RefractoryPeripheralT cell Lymphoma: A Singl e-arm, Multicenter Study Toshihiko Doi et al. PhaseI Studyof the FocalAdhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patie nts with Advanced or MetastaticSolidTumors Y. Louise Wan et al. Combination Treatment with an Antibody–Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Modelof Ovarian Cancer
In the year from October 2018 to September 2019, articles from the journal were downloaded more than 83,000 times in total. The quality of articles published in the journal is also reflected in its most recent impact factor (3.683). Targeted Oncology is currently ranked 80th in the ‘Oncology’ category (of 230 journals). We thank the authors who have contributed articles to Targeted Oncology over the course of 2019. The skill and dedication of all authors are critical to the continued publication of the journal. The quality of published articles is also testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal’s content is held to the highest possible standard. We would like to thank the following ind
Data Loading...
